New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

Buzzworthy developments of the past few days.

Members of C-suites around the world are making room for a new teammate: the CAIO. In healthcare, some organizations are hiring for the even more specialized position of CHAIO, for chief health AI officer.

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State. 

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said. 

Going by criteria set and applied by Money magazine, only two of America’s 6,000 or so hospitals deserve the title “best of the best.”